Exosome Diagnostics Inc.
Waltham, MA Part of Mdxhealth, Inc.
- UEI
- TCKUCULVVY39
- CAGE
- 554U8
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Research and Diagnostic Systems Inc, ranks #96 in NAICS 621511
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
Irvine, CA
LQGYDJJ9K8Q6
-
Parent
Irvine, CA
LQGYDJJ9K8Q6
- SAM.gov registration date
- Physical address
- 266 2nd Ave #200, Waltham, MA 02451, USA
- Website
- mdxhealth.com
- Founded
- 2004
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $64,957 |
| FY2026 | $417,484 |
| FY2025 | $294,800 |
| FY2024 | $313,384 |
| FY2023 | $36,073 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $482,441 |
Contract vehicles
No active vehicles.
1 expired vehicle
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The General Hospital Corporation | R01CA291826 | $66,400 | |
| The General Hospital Corporation | U01CA284982 | $286,000 | |
| The General Hospital Corporation | R01CA237500 | $136,037 | |
| The General Hospital Corporation | R01CA239078 | $209,273 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Mdxhealth, Inc. | Irvine, CA | 621511 Medical Laboratories |
| Genomic Health, Inc. | Redwood City, CA | 621511 Medical Laboratories |
| Decipher Biosciences, Inc. | San Diego, CA | 621511 Medical Laboratories |
| Exact Sciences Laboratories, LLC | Madison, WI | 621511 Medical Laboratories |
| Natera Inc. | Austin, TX | 621511 Medical Laboratories |
About the company
Exosome Diagnostics Inc., a subsidiary of foreign-owned Mdxhealth Inc., delivers non-invasive liquid biopsy testing for prostate cancer screening to the Department of Veterans Affairs as a prime contractor (83% of recent awards) under the GSA Medical Laboratory Testing and Analysis Services schedule. The company operates on a full-and-open basis with no set-aside designations across its federal footprint, competing predominantly through sole-source procurements that reflect its proprietary exosomal RNA biomarker diagnostic capabilities.
Exosome Diagnostics' core federal capability is ExoDx Prostate IntelliScore, a urine-based liquid biopsy test that analyzes extracellular vesicle RNA markers to assess clinically significant prostate cancer risk in veterans age 50 and older with PSA levels between 2 and 10 ng/mL. The test operates as a non-invasive alternative to digital rectal examination and is delivered via home collection kits with prepaid return shipping and results reporting within five business days. Representative prime work includes a $692,149.52 delivery order from Veterans Integrated Service Network 6 (awarded May 2022, running through September 2026 at Richmond, Virginia); a $1.35 million Blanket Purchase Agreement with Veterans Integrated Service Network 1 (established December 2023, running through December 2028, structured for approximately 1,800 tests over five years at West Haven, Connecticut and Waltham, Massachusetts); and a $1.12 million BPA with Veterans Integrated Service Network 19 (awarded September 2026, running through September 2027, covering nine laboratory facilities across Colorado, Montana, Oklahoma, and Utah). All contracts carry firm fixed-price terms and CLIA certification, Medicare/Medicaid approval, and HIPAA compliance requirements.
Customer concentration is heavily weighted to the VA. The top five funding entities account for 78% of awards by count; Department of Veterans Affairs Veterans Integrated Service Network 1 leads by both volume (5 awards, $1.8 million) and frequency, but Department of Veterans Affairs Veterans Integrated Service Network 12 anchors the potential-value rankings with a single $2.3 million award. The National Institutes of Health National Cancer Institute accounts for 4 awards, though dollar values are not specified in the source. Across 23 total awards in the source data, combined potential value is $7.4 million, with 21 task orders placed under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule, representing 80% of the combined potential value.
Activity has grown unevenly — two awards in both 2022 and 2023, six in 2024, two in 2025, and four in 2026 — with only one award (valued at $7 thousand) reaching ultimate completion within the next twenty-four months, presenting minimal near-term recompete exposure. Exosome Diagnostics also acts as a sub-recipient on two federal research grants through The General Hospital Corporation (Massachusetts General Hospital). In June 2025, the company received a sub-award for collaborative development of GLIscan, a multiplexed blood-based assay targeting brain tumor biomarkers (IDH1 R132H, EGFRvIII, and TERT mutations), performing assay development, parallel validation in patient plasma samples, and CLIA validation planning. In November 2023, the company received a sub-award for extracellular vesicle analysis and ovarian cancer detection, providing technical support for the nPLEX system, sensor chip production, and EV isolation and profiling for both cell cultures and clinical samples. The company's headquarters is in Waltham, Massachusetts, with performance locations spanning multiple VA facilities and research institutions.
Quick answers
Is Exosome Diagnostics Inc. registered in SAM.gov?
Yes. Exosome Diagnostics Inc.'s SAM.gov registration is active through October 21, 2027.
Which contract vehicles does Exosome Diagnostics Inc. hold?
Exosome Diagnostics Inc. holds a place on 1 federal contract vehicle: FSS-621-II.
How much has Exosome Diagnostics Inc. received in federal contracts?
Federal contracts obligated $294,800 to Exosome Diagnostics Inc. in fiscal year 2025 and $1,126,697 in fiscal years 2023 through 2027.
How does Exosome Diagnostics Inc. rank among federal contractors?
Exosome Diagnostics Inc.'s parent company, Research and Diagnostic Systems Inc, ranked #96 in NAICS 621511 in FY2025.
What is Exosome Diagnostics Inc.'s most recent federal award?
Exosome Diagnostics Inc.'s most recent federal contract award is VISN 19 non-invasive prostate testing (36C25926N0479), from Veterans Integrated Service Network 19 (VHA), on September 15, 2026.
On GovTribe
See Exosome Diagnostics Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors